康希诺生物股份公司 一、"聚焦主营业务，以创新为核心驱动力"方面 关于公司 2025 年度提质增效重回报专项行动方案的 半年度评估报告 2025 年上半年，随着流脑疫苗产品的推广和市场终端选择，尤其是核心产品 曼海欣®作为中国市场上唯一的四价流脑结合疫苗，市场占有率不断提升，两款流 脑结合疫苗实现销售收入约 36,367.48 万元，同比增长 38.43%，公司实现营业收 入 38,232.99 万元，同比增长 26.00%。同时，公司归属于上市公司股东的净亏损 为 1,348.54 万元，亏损同比大幅收窄 94.02%。公司持续加强渠道拓展及学术推广 工作，通过打造品牌效应持续推进曼海欣®的国内商业化进程。海外商业化方面， 公司以东南亚、中东及南美为核心目标市场，加速推进曼海欣®的海外注册与商业 化落地。今年 2 月，曼海欣®成功获得印尼 Halal 认证；3 月，公司与沙特阿拉伯 SPIMACO 公司签署疫苗合作协议，共同推动曼海欣®落地中东及北非地区市场。 与此同时，公司持续拓展曼海欣®的适用人群范围，其 4-6 岁（至 83 月龄）的补 充申请审批正有序进行，并计划未来进一步提交 7-59 岁扩龄申请 ...

一、监事会会议召开情况 康希诺生物股份公司（以下简称"公司"）第三届监事会第八次会议于 2025 年 8 月 20 日在公司会议室以现场及通讯的方式召开，会议通知已于会议召开 10 日前以电子邮件形式送达全体监事。本次会议由监事会主席肖治召集，应到监事 3 人，实到监事 3 人。会议的召集、召开和表决程序符合《中华人民共和国公司 法》等法律法规及规范性文件和《康希诺生物股份公司章程》的规定，合法有效。 二、监事会会议审议情况 经与会监事审议，逐项表决，形成决议如下： （一）《关于 2025 年半年度报告及摘要的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 证券代码：688185 证券简称：康希诺 公告编号：2025-019 康希诺生物股份公司 第三届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康希诺生物股份公司 2025 年半年度报告》及其摘要。 （二）《关于 2025 年半年度募集资金存放与使 ...

Core Viewpoint - 康希诺 reported a revenue of 382 million yuan for the first half of 2025, representing a year-on-year growth of 26% [1] Financial Performance - The net loss attributable to shareholders narrowed to 13.49 million yuan, compared to the previous year [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 85.90 million yuan [1] - Basic loss per share was 0.05 yuan [1] Operational Efficiency - The comprehensive gross profit margin for the reporting period was 82.54%, an increase of 12.68 percentage points year-on-year [1] - The company implemented cost reduction and efficiency enhancement measures, resulting in savings across multiple expense categories during the reporting period [1]

康希诺（SH 688185，收盘价：82.99元）8月20日晚间发布半年度业绩报告称，2025年上半年营业收入 约3.82亿元，同比增加26%；归属于上市公司股东的净利润亏损约1349万元；基本每股收益亏损0.05 元。2024年同期营业收入约3.03亿元；归属于上市公司股东的净利润亏损约2.25亿元；基本每股收益亏 损0.91元。 （文章来源：每日经济新闻） ...

格隆汇8月20日丨康希诺(688185.SH)公布，在保证不影响募集资金投资项目实施、募集资金安全的前提 下，公司拟使用最高34,000万元的暂时闲置募集资金进行现金管理，使用期限不超过12个月，在前述额 度及期限范围内，公司可以循环滚动使用。 ...

康希诺生物股份公司2025 年半年度报告 公司代码：688185 公司简称：康希诺 康希诺生物股份公司 2025 年半年度报告 1 / 184 康希诺生物股份公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生 重大不利影响的风险因素，敬请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人XUEFENG YU（宇学峰）、主管会计工作负责人刘明及会计机构负责人（会计 主管人员）高蓓蓓声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 九 ...

康希诺公告，2025年上半年营业收入3.82亿元，同比增长26.00%。归属于上市公司股东的净亏损 1348.54万元，上年同期净亏损2.25亿元。研发投入占营业收入的比例48.03%，减少33.82个百分点。 ...

Group 1 - The overall number of vaccine batch approvals in the first half of 2025 is 1,629, representing a year-on-year decrease of 17% [1] - Certain vaccines, such as rabies and HPV vaccines, have seen significant growth in batch approvals, while others like polio, meningitis, and measles-mumps-rubella vaccines have experienced substantial declines [1] - Several key vaccines have received approval for market launch in the first half of the year, including CanSino's PCV13 and Wantai's 9-valent HPV vaccine [1] Group 2 - Multiple products are currently in the review stage for market approval, including Zhifei's PCV15 and MCV4, as well as Kangtai's IPV and quadrivalent influenza vaccines [1] - It is anticipated that sales of certain products in the second half of 2025 may improve year-on-year, driven by new product launches contributing to revenue growth [1] - The ongoing development of innovative vaccine pipelines and expectations for external licensing are areas of interest, along with the implications of recent equity changes in some companies and the potential impact of new shareholders [1]

Summary of Key Points from the Conference Call Company Overview - The conference call discusses 康希诺 (CanSino), a biopharmaceutical company specializing in vaccine development and commercialization. Industry Insights - The vaccine market is expected to expand significantly, particularly for products like MCV4 and PCV13, driven by rising demand and economic recovery in China. Key Products and Developments 1. **MCV4 Vaccine** - MCV4 vaccine shows superior immunogenicity and durability in children under two compared to traditional vaccines, with sales projected to grow from 560 million CNY in 2023 to over 1 billion CNY in 2024 [2][3][5] - It has received expert consensus recommendation and is expected to replace existing meningococcal vaccines [2][3] 2. **PCV13 Vaccine** - PCV13 utilizes multi-component and dual-carrier technology, aiming to produce higher specificity antibodies in infants and address immune suppression issues from co-administration with other vaccines [2][3][6] - The overall market for PCV13 was nearly 7 billion CNY in 2022, making it the top vaccine in China that year [3][6] 3. **PDP1 Pneumococcal Vaccine** - PDP1 is in Phase I clinical trials, demonstrating good safety and high antibody levels, with potential to cover over 98% of pneumococcal strains [2][4][7] - It shows broad-spectrum efficacy and public health value [4][7] 4. **DPTCP Vaccine** - The DPTCP vaccine is developed to meet the increasing demand for a more durable and safer pertussis vaccine, utilizing a purified antigen approach [2][4][8] - This vaccine is positioned to replace older generation vaccines and imported pentavalent vaccines [4][9] 5. **VLP Polio Vaccine** - The VLP (Virus-Like Particle) polio vaccine is in Phase I clinical trials and has received funding from the Gates Foundation and WHO, offering high safety and immunogenicity [2][10] - It avoids the risks associated with traditional oral and inactivated polio vaccines [10] 6. **Shingles Vaccine** - CanSino is developing a shingles vaccine using adenovirus vector technology, with clinical trials ongoing in Canada [2][11] - Preliminary data indicates that its immunogenicity is comparable to GSK's Shingrix, which has a high adverse event rate [11] Market Position and Future Outlook - CanSino is positioned as the third domestic and fourth overall listed vaccine company in China, with significant market share potential in the expanding PCV market [4][6] - The company is focused on global market expansion and innovation in vaccine development, with a strong pipeline of products that leverage advanced technologies [2][12] - Investors are encouraged to pay attention to companies like CanSino that possess advanced R&D capabilities and differentiated product offerings in the healthcare sector [3][12]

Group 1 - The Shanghai Composite Index fell by 0.46% to close at 3666.44 points, while the Hang Seng Index decreased by 0.37% to 25519.32 points [1] - CanSino Biologics has an AH premium of 88.3%, ranking 35th among AH shares. The A-share closed at 83.93 yuan, down 1.33%, and the H-share closed at 48.76 HKD, down 0.77% [1] - CanSino Biologics, founded in 2009 in China, focuses on providing innovative, high-quality, and accessible vaccines for the prevention and treatment of infectious diseases. The company's mission is to offer innovative and quality vaccines globally, aiming for "innovation without end, a world without epidemics" [1] Group 2 - CanSino Biologics is listed on both the Hong Kong Stock Exchange (H-share, stock code 6185.HK) and the Shanghai Stock Exchange's STAR Market (A-share, stock code 688185), making it the first "A+H" vaccine stock since the launch of the STAR Market in China [1]